Medical News TodayImmunotherapy found safe for type 1 diabetes in landmark trialMedical News TodayA new trial investigates the safety profile of proinsulin peptide immunotherapy for treating type 1 diabetes, and the results are encouraging.Immunotherap… Continue reading
New Scientist |
This is why the first CRISPR baby won’t be born in the US
New Scientist Hopes are high that gene editing embryos can ease inherited disease. The first such babies are likely within five years, but not in the US, says Jim Kozubek. CRISPR-edited embryos. Free of the disease-causing mutation. OHSU. The media well and truly … |
News-Medical.net |
Immunotherapy shows promise in treatment of Type 1 diabetes
News-Medical.net Around 1.25 million Americans are living with type 1 diabetes and 40000 new cases are detected each year. In this condition body’s own immune system attacks … Immunotherapy Promising for Diabetes: Study | The Scientist …The Scientist Immunotherapy for type I diabetes safe and well-tolerated, report …EPM Magazine |
Inverse |
Synthetic DNA Enables the Latest Horrifying Cybersecurity Threat
Inverse The electronic and molecular worlds are converging as scientists refine techniques for sequencing and synthesizing DNA (i.e. reading and writing DNA). Synthetic biology is an important field — advancements will help us fight diseases and disorders … Malware Stored in Synthetic DNA Can Take Over a PC, Researchers FindWall Street Journal (subscription) |
CBS News |
Study finds immunotherapy may prevent Type 1 diabetes | The …
The Seattle Times After a quarter-century of failed efforts to treat diabetes with an immune therapy, the experimental treatment appeared to quell the immune system’s assaults on … 8 things you need to know about diabetes right now – Yahoo Style UKYahoo Style UK |
|
Cancer Research UK, Biotecnol to Advance Solid Tumor Immunotherapy Into the Clinic
Genetic Engineering & Biotechnology News Cancer Research UK and Biotecnol said they will advance an immuno-oncology treatment for lung cancers and other solid tumors into early phase clinical trials, through a collaboration whose value was not disclosed. Cancer Research UK will support early … |